NCT07116083 µQFR for Branch Stenosis After Single Stent in Bifurcation Lesions
| NCT ID | NCT07116083 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Zhongshan Hospital |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 290 participants |
| Start Date | 2025-08-13 |
| Primary Completion | 2026-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 290 participants in total. It began in 2025-08-13 with a primary completion date of 2026-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Murray-law based single-view quantitative flow ratio (µQFR) has been recommended for guiding percutaneous coronary intervention (PCI) in selective patients. However, it's reliability has not been validated in bifurcation lesions which present complex anatomy and flluid conditions before and after PCI. The goal of this study is to investigate the diagnostic performance of µQFR in side branch after single-stent treatment for bifurcation lesions in patient with obstructive coronary artery diseases.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years and provision of written informed consent for biospecimen donation upon hospital admission. 2. Clinical suspicion or diagnosis of CAD requiring coronary angiography and physiological assessment. 3. Angiographically confirmed true bifurcation lesions, including but not limited to: left main-left anterior descending-left circumflex (LM-LAD-LCx), left anterior descending-diagonal (LAD-Dg), left circumflex-obtuse marginal (LCx-OM), and right coronary artery-posterior left ventricular-posterior descending artery (RCA-PLV-PDA). 4. Bifurcation lesion vessel diameter ≥ 2.5 mm with visually estimated angiographic diameter stenosis ≥ 50%. Exclusion Criteria: 1. Acute myocardial infarction. 2. Cardiogenic shock or severe heart failure (Killip class IV). 3. Serum creatinine \> 150 μmol/L or estimated glomerular filtration rate (eGFR) \< 45 mL/min/1.73 m² calculated using the CKD-EPI formula. 4. Known allergy to iodinated contrast media. 5. History of coronary artery bypass graft surgery.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07116083 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07116083 currently recruiting?
Yes, NCT07116083 is actively recruiting participants. Contact the research team at li.chenguang@zs-hospital.sh.cn for enrollment information.
Where is the NCT07116083 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07116083 clinical trial?
NCT07116083 is sponsored by Shanghai Zhongshan Hospital. The trial plans to enroll 290 participants.